HSPA1B and non-small cell lung carcinoma: We also observed that both decreasing the levels of HSPA1 and HSPA2 (separately, Fig. 2G–I; or in combination, Fig. 3E), as well as blocking HSPAs activity by VER (Figs 6B, S1C,D) did not alter NSCLC cells sensitivity to CPT but instead made them more resistant to CDDP.